Ligand Pharmaceuticals Inc
LGND· Nasdaq
LGNDLigand Pharmaceuticals Inc
Filed Feb 29, 2024 · 10-K · 60 days after period end · 0000886163-24-000009
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|
| Revenue | $28.10M | $50.38M | $56.40M | $69.99M |
| Net Income | $18.19M | -$17.49M | -$5.42M | $5.76M |
| EPS Diluted | — | -$0.86 | -$0.19 | $0.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 29, 2024 · 60 d after period end
